1. The effect of abatacept on T-cell activation is not long-lived in vivo .
- Author
-
da Rosa LC, Scales HE, Benson RA, Brewer JM, McInnes IB, and Garside P
- Abstract
Abatacept, a co-stimulatory blocker comprising the extracellular portion of human CTLA-4 linked to the Fc region of IgG1, is approved for the treatment of rheumatoid arthritis. By impairing the interaction between CD28 on T cells and CD80/CD86 on APCs, its mechanisms of action include the suppression of follicular T helper cells (preventing the breach of self-tolerance in B cells), inhibition of cell cycle progression holding T cells in a state described as 'induced naïve' and reduction in DC conditioning. However, less is known about how long these inhibitory effects might last, which is a critical question for therapeutic use in patients. Herein, employing a murine model of OVA-induced DTH, we demonstrate that the effect of abatacept is short-lived in vivo and that the inhibitory effects diminish markedly when treatment is ceased., Competing Interests: The authors declare that there is no conflict of interest., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Immunology.)
- Published
- 2024
- Full Text
- View/download PDF